A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Immigrant advocacy groups filed the lawsuit last week accusing the Trump administration of systematically targeting ...

President Donald Trump arrived Friday in Texas for a firsthand look at the devastation from the state's catastrophic flooding ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...